F Perrone
Overview
Explore the profile of F Perrone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
2156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pellegrino B, Capoluongo E, Bagnoli M, Arenare L, Califano D, Scambia G, et al.
ESMO Open
. 2025 Jan;
10(1):104091.
PMID: 39754985
Background: Ovarian cancer (OvC) constitutes significant management challenges primarily due to its late-stage diagnosis and the development of resistance to chemotherapy. The standard treatment regimen typically includes carboplatin and paclitaxel,...
2.
Gravina A, Gargiulo P, De Laurentiis M, Arenare L, De Placido S, Orditura M, et al.
ESMO Open
. 2025 Jan;
10(1):104085.
PMID: 39754976
Background: The Hormonal Bone Effects (HOBOE) study tested whether adjuvant triptorelin plus either letrozole (L) or zoledronic acid (Z) plus L (ZL) was more effective than tamoxifen (T) in premenopausal...
3.
Arenare L, Di Liello R, De Placido P, Gridelli C, Morabito A, Pignata S, et al.
ESMO Open
. 2024 Dec;
9(11):103693.
PMID: 39617531
No abstract available.
4.
Paratore C, Zichi C, Schiavone R, Caglio A, Gamba T, Bombaci S, et al.
ESMO Open
. 2024 Jul;
9(8):103654.
PMID: 39067259
Background: Despite the interest from the scientific community and regulatory agencies, limited data are available on the association between health-related quality-of-life (QoL) results, outcome of efficacy and drug approvals. Materials...
5.
Natalicchio A, Marrano N, Montagnani M, Gallo M, Faggiano A, Zatelli M, et al.
J Endocrinol Invest
. 2024 Jun;
47(12):2915-2928.
PMID: 38935200
Background: Increasing evidence suggests that diabetes increases the risk of developing different types of cancer. Hyperinsulinemia, hyperglycemia and chronic inflammation, characteristic of diabetes, could represent possible mechanisms involved in cancer...
6.
Busico A, Gasparini P, Rausa E, Cattaneo L, Bozzi F, Silvestri M, et al.
Sci Rep
. 2024 Jun;
14(1):13138.
PMID: 38849509
Colorectal cancer (CRC) is a global health concern, and the incidence of early onset (EO) CRC, has an upward trend. This study delves into the genomic landscape of EO-CRC, specifically...
7.
Pignata S, Califano D, Lorusso D, Arenare L, Bartoletti M, De Giorgi U, et al.
Ann Oncol
. 2024 May;
35(7):667-676.
PMID: 38704093
Background: Immunotherapy combined with chemotherapy significantly improves progression-free survival (PFS) compared to first-line chemotherapy alone in advanced endometrial cancer (EC), with a much larger effect size in microsatellite instability-high (MSI-H)...
8.
Carrera P, Curigliano G, Santini D, Sharp L, Chan R, Pisu M, et al.
ESMO Open
. 2024 Apr;
9(5):102992.
PMID: 38626634
Background: Financial toxicity, defined as both the objective financial burden and subjective financial distress from a cancer diagnosis and its treatment, is a topic of interest in the assessment of...
9.
Arenare L, Di Liello R, De Placido P, Gridelli C, Morabito A, Pignata S, et al.
ESMO Open
. 2024 Mar;
9(3):102941.
PMID: 38452437
Background: Oncologists tend to under-report subjective symptoms during cancer treatment. This study describes the under-reporting rate of selected symptoms and explores its association with overall survival (OS). A secondary aim...
10.
Arenare L, Porta C, Barberio D, Terzolo S, Zagonel V, Pisconti S, et al.
ESMO Open
. 2023 Dec;
8(6):102192.
PMID: 38052104
Background: The Patient Reported Outcome for Fighting FInancial Toxicity (PROFFIT) questionnaire was developed to measure financial toxicity (FT) and identify its determinants. The aim of the present study was to...